In 2019, the US Food and Drug Administration (FDA) approved Janssen Pharmaceutical, Spravato (esketamine, the S isomer of ketamine) CIII nasal spray to treat depressive symptoms in adults with ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now. Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal ...

However, no glutamatergic modulator tested to date has matched the rapid, robust and sustained antidepressant effects of (R,S)-ketamine and esketamine. In addition, the breadth of therapeutic effects ...